Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
25 Novembre 2019 - 7:21PM
Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual
Healthcare Conference
Kiadis Pharma to present at the 2019
Piper Jaffray 31st Annual Healthcare Conference
Amsterdam, The Netherlands, November 25,
2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”)
(Euronext Amsterdam and Brussels: KDS), a clinical stage
biopharmaceutical company, today announces that Kiadis will
participate in the 2019 Piper Jaffray 31st Annual Healthcare
Conference. Arthur Lahr, the company’s chief executive officer,
will participate in a fireside chat and host one-on-one meetings
with investors on Tuesday, December 3rd at the Lotte New York
Palace in New York, NY.
The presentation will be webcast live and may be
accessed by visiting the "For Investors" section of the Company's
website under the "Events" tab at https://www.kiadis.com/. A replay
of the webcast will be available for 90 days.
Date: Tuesday, December 3,
2019Time: 2:30 P.M. ETWebcast:
https://event.webcasts.com/starthere.jsp?ei=1273957&tp_key=f098fa6bba
Kiadis Contacts:
Kiadis Pharma:
Maryann Cimino, Manager, Corporate AffairsTel: +1 (617)
710-7305m.cimino@kiadis.com |
Optimum Strategic
Communications:Mary Clark, Supriya Mathur, Hollie VileTel:
+44 203 950 9144David Brilleslijper (Amsterdam)Tel: +31 610 942
514kiadis@optimumcomms.com |
About Kiadis
Founded in 1997, Kiadis Pharma is building a
fully integrated biopharmaceutical company committed to developing
innovative therapies for patients with life-threatening diseases.
With headquarters in Amsterdam, the Netherlands, and offices and
activities in the US and across Europe, Kiadis Pharma is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis Pharma is listed on the regulated market
of Euronext Amsterdam and Euronext Brussels since July 2, 2015,
under the symbol KDS. Learn more at kiadis.com.
Forward Looking
StatementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma’s
or, as appropriate, Kiadis Pharma’s directors’ current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis Pharma expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither Kiadis Pharma nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.